Partnering with OpenEvidence: A Life-Saving Healthcare Revolution

• 25%+ of U.S. doctors use OpenEvidence ~1 year post-launch.
  • 35,000 verified new doctors onboarded per month.
  • Growth entirely word-of-mouth — zero traditional marketing.
• Searches 35M peer-reviewed papers; trained on NEJM.
  • Never hallucinates — stays silent when evidence is inconclusive.
• Co-founder Daniel Nadler: previously built Kensho (acquired by S&P 2018).
• Sequoia led Series A as first institutional investor.
• Free to all U.S. doctors — monetization not via physicians.
  • Revenue model: sell query patterns to pharma, license to health systems.
• Tandem integration: evidence-based prescribing → prior auth in one workflow.
  • Closing the gap between clinical decision and insurance authorization.
• Positioned as iPhone-level adoption velocity in medicine.

X discourse

• @HealthcareAIGuy: “OpenEvidence expanding into insurance authorizations via partnership with Tandem. Race to all-in-one health AI platform” (217 likes)
• @HealthcareAIGuy: “OpenEvidence: ChatGPT for clinicians, pure-play health AI on Enterprise Tech 30 list.” (63 likes)
• @zakkohane: “Health systems’ AI governance backlog on tools like OpenEvidence risks patient data. Make them safely accessible.” (53 likes)
• @EvidenceOpen: “Partnering with Tandem to connect evidence-based prescribing to prior auth in single workflow.” (38 likes)
• @thoughtson_tech: “OpenEvidence sells query patterns to pharma, licenses to health systems. Free now, but shift coming.” (0 likes)
• @dr_nikhilshah: “@EvidenceOpen and @HeyEpic should collaborate for complete healthcare stack with navigator in charts.” (1 likes)

Pat Grady, Sequoia Capital · 2025-02-19 · Read on sequoiacap.com